

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Zylox-Tonbridge Medical Technology Co., Ltd.**

**歸創通橋醫療科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2190)**

### **RETIREMENT AND PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS**

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”).

#### **RETIREMENT OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company hereby announces that Mr. Hongze Liang (“**Mr. Liang**”) has indicated he will not offer himself for re-election as an independent non-executive Director at the upcoming annual general meeting of the Company (the “**AGM**”) due to other work commitments. Accordingly, Mr. Liang will cease to be an independent non-executive Director and a member of each of the audit committee (the “**Audit Committee**”) and the remuneration committee (the “**Remuneration Committee**”) of the Company upon conclusion of the AGM.

Mr. Liang has confirmed that he has no disagreement with the Board, and there is no other matter relating to his retirement that needs to be brought to the attention of the Stock Exchange and the shareholders of the Company (the “**Shareholders**”).

The Board would like to take this opportunity to express its sincere gratitude to Mr. Liang for his valuable contribution to the Group during his tenure of office.

## **PROPOSED APPOINTMENT OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR**

The Board has also considered and resolved, with the recommendation of the nomination committee of the Company, to nominate Dr. Xiang Qian (錢湘) (“**Dr. Qian**”) as a candidate for independent non-executive Director of the second session of the Board. In accordance with the requirements of relevant laws, regulations, regulatory rules and the articles of association of the Company (the “**Articles of Association**”), the appointment of Dr. Qian as an independent non-executive Director is subject to the approval of the Shareholders at the general meeting. The relevant ordinary resolution will be put forward at the AGM for Shareholders’ consideration and approval.

The biographical details of Dr. Qian are as follows:

**Dr. Xiang Qian (錢湘)**, aged 49, is a renowned Physician and Clinical Professor at Stanford University, specializing in Pain Medicine and Interventional Neurosurgery since 2009. Dr. Qian is also the professor and Co-Director of Stanford Wearable Electronics Initiative (eWEAR) where he focuses on developing wearable and implantable electronics to address the medical needs, particularly in the field of neurology and pain medicine. Additionally, he also serves as the inaugural Stanford Medicine Endowed Director since 2021.

Dr. Qian specializes in developing novel therapies for various chronic pain conditions, and lectures internationally on these topics. Dr. Qian’s clinical interests include the treatment of acute and chronic pain, with special interest in migraine, headache, trigeminal neuralgia, glossopharyngeal neuralgia, hemifacial spasm, atypical facial pain, cancer pain, back pain, joint pain, nerve pain, and others.

Further, Dr. Qian holds the position of Medical Director of Stanford International Medical Services, where he has been working in collaboration with members from all subspecialties and hospital administrations to help deliver care for international patients and promote international collaborations.

Dr. Qian also founded the Chinese American Physicians’ Society in 2014 to foster exchanges of medical knowledge and promote medical innovation. In 2019, Dr. Qian was awarded the Fok Ying-Tung Prize The World Outstanding Chinese Doctor Award in recognition of his works and contributions.

Dr. Qian obtained Bachelor’s and Master’s degrees in Clinical Medicine from the Zhejiang University School of Medicine in 1997 and 1999, respectively, and a Doctor of Philosophy in Physiology and Biophysics from the University of Miami Miller School of Medicine in 2004. From 2004 to 2008, Dr. Qian went through postdoctoral fellowship training in

Neuroscience at the University of California, San Francisco. Dr. Qian then completed his internship at an affiliated hospital of the Harvard Medical School in 2008. At Stanford University, Dr. Qian completed his residency in 2012 and his fellowship training in 2013.

The term of office of Dr. Qian shall commence from the date of approval at the AGM until the expiry of the term of the second session of the Board. Dr. Qian shall be eligible for re-election upon the expiry of his term of office. The Company will enter into a service contract with Dr. Qian upon approval at the AGM. Dr. Qian will receive a remuneration from the Company for acting as an independent non-executive Director, which will be determined by the Board, the authorization of which is subject to the approval of the Shareholders at the AGM, and in line with the remuneration paid to other independent non-executive Directors.

Save as disclosed above, Dr. Qian does not have any relationship with any Director, supervisor, senior management or substantial or controlling Shareholders of the Company, nor does he hold any other positions in the Company or any of its subsidiaries, or hold any directorships in other listed companies in the last three years.

As at the date of this announcement, Dr. Qian does not have or is not deemed to have any interests or short positions in the shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance) (Chapter 571 of the Laws of Hong Kong).

Dr. Qian confirmed that (i) he met the independence criteria as set out in Rule 3.13 of the Listing Rules; (ii) he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment.

Save as disclosed above, the Board is not aware of any other matters in relation to the proposed appointment of Dr. Qian that need to be brought to the attention of the Shareholders nor any information that is required to be disclosed pursuant to Rules 13.51(2) (h) to (v) of the Listing Rules.

Following to the approval of Dr. Qian's appointment as an independent non-executive Director by the Shareholders at the AGM, Dr. Qian will also be appointed as a member of each of the Audit Committee and the Remuneration Committee.

A circular containing, among other things, information relating to (i) the appointment of Dr. Qian as an independent non-executive Director; and (ii) the notice convening the AGM together with proxy form shall be published on the websites of the Company and the Stock Exchange in due course.

By order of the Board  
**Zylox-Tonbridge Medical Technology Co., Ltd.**  
**Dr. Jonathon Zhong Zhao**  
*Chairman and Executive Director*

Hong Kong, May 9, 2024

*As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Mr. Stephen Hui Wang, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive Directors.*